Clinical trials data – raw or redacted?

In this issue:

Clinical trials transparency: EMA accused of U-turn
For years, Europe’s drug regulators pushed for the proactive publication of results from clinical trials. As the EMA prepares to present its new policy in the area, however, it has come under fire from health technology assessors and the European Ombudsman, who say the planned rules could make transparency even worse. The guidelines foresee allowing companies to redact “commercially confidential” information, while requiring researchers to sign agreements not to publish or disseminate some of the data.